UNIVERSITY OF BIRMINGHAM

Research at Birmingham

The Histone Methyltransferase KMT2B Is Required for RNA Polymerase II Association and Protection from DNA Methylation at the MagohB CpG Island Promoter

Ladopoulos, Vasileios; Hofemeister, Helmut; Hoogenkamp, Maarten; Riggs, Arthur D; Stewart, A Francis; Bonifer, Constanze

Document Version
Publisher's PDF, also known as Version of record

Link to publication on Research at Birmingham portal

The Histone Methyltransferase KMT2B Is Required for RNA Polymerase II Association and Protection from DNA Methylation at the *MagohB* CpG Island Promoter

Vasileios Ladopoulos,[a] Helmut Hofemeister,[b] Maarten Hoogenkamp,[a] Arthur D. Riggs,[c] A. Francis Stewart,[b] Constanze Bonifer[a]

School of Cancer Sciences, Institute of Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom[a]; Genomics, Technische Universitaet Dresden, BioInnovation Zentrum, Dresden, Germany[b]; Department of Biology, Beckman Institute of City of Hope, Duarte, California, USA[c]

KMT2B (MLL2/WBP7) is a member of the MLL subfamily of H3K4-specific histone lysine methyltransferases (KMT2) and is vital for normal embryonic development in the mouse. To gain insight into the molecular mechanism underlying KMT2B function, we focused on *MagohB*, which is controlled by a CpG island promoter. We show that in cells lacking *Mll2*—the gene encoding KMT2B—the *MagohB* promoter resides in inaccessible chromatin and is methylated. To dissect the molecular events leading to the establishment of silencing, we performed kinetic studies in *Mll2*-conditional-knockout embryonic stem cells. KMT2B depletion was followed by the loss of the active chromatin marks and progressive loss of RNA polymerase II binding with a concomitant downregulation of *MagohB* expression. Once the active chromatin marks were lost, the *MagohB* promoter was rapidly methylated. We demonstrate that in the presence of KMT2B, neither transcription elongation nor RNA polymerase II binding is required to maintain H3K4 trimethylation at the *MagohB* promoter and protect it from DNA methylation. Reexpression of KMT2B was sufficient to reinstate an active *MagohB* promoter. Our study provides a paradigm for the idea that KMT2 proteins are crucial components for establishing and maintaining the transcriptionally active and unmethylated state of CpG island promoters.

Histone H3 lysine 4 trimethylation (H3K4me₃) has been associated with transcriptionally active promoters (1, 2). Mammals have at least 6 different H3K4-specific methyltransferases; in mice these are KMT2A (ALL1/CXXC7/MLL1), KMT2B (MLL2/WBP7), KMT2C (MLL3), KMT2D (MLL4), KMT2E (SET1A), and KMT2F (SET1B). Murine *Mll2* is a paralogue of *Mll1* and is the orthologue of human *MLL4*. *Mll2* resides on mouse chromosome 7 (mm9 chr7: 31353874 to 31369215) and codes for the KMT2B methltransferase. These enzymes have at least some nonredundant functions, as depletion of either KMT2A or KMT2B is embryonically lethal (3–5). KMT2A is the most studied of the H3K4 methyltransferases, as it is involved in various leukemogenic translocations (6, 7). These aberrant fusion proteins function by recruiting a constitutively active, transcriptional elongation-promoting complex to promoters (8–10).

In *Saccharomyces cerevisiae*, Set1 is the only enzyme responsible for H3K4me₃ deposition and is recruited to the initiating form of RNA polymerase II (Pol II) (11), suggesting that the H3K4me₃ mark is deposited after transcription has initiated. In mice, depletion of KMT2A results in transcriptional silencing, abnormal RNA polymerase II distribution, loss of histone acetylation, and CpG island promoter methylation on a subset of the *Hox* genes (12–14). These results suggest that KMT2A recruitment is crucial for the association of the basal transcription machinery and is involved in setting up a permissive chromatin landscape for transcription as well as preventing DNA methylation. However, direct evidence for this idea has so far been lacking.

In contrast to KMT2A, the KMT2B function is less characterized. In embryonic stem (ES) cells, only a small number of genes are significantly downregulated in response to KMT2B depletion, the most prominent of which is *MagohB* (15). *MagohB* is regulated by a CpG island promoter, and it is expressed in all tissues examined so far, including ES cells (15). *MagohB* expression is absolutely dependent on KMT2B in ES cells, with no apparent functional redundancy from other H3K4 methyltransferases. *MagohB* transcriptional silencing in the absence of KMT2B is characterized by loss of H3K4me₃ and increased DNA methylation over the *MagohB* CpG island promoter (15). This phenomenon is similar to what has been observed on the *Hox* genes in cells lacking KMT2A (12–14). However, the order of events leading to the establishment of the silenced state is unknown in either case. In addition, the interdependency between RNA polymerase II binding and MLL2 association is unclear. We used ES cells carrying a conditional allele of *Mll2* to address these questions and performed kinetic experiments aimed at dissecting the molecular events leading to *MagohB* silencing and DNA methylation. Here we present direct evidence that the presence of KMT2B is required for the stable maintenance of the basal transcription machinery and for maintaining low levels of DNA methylation. Our experiments demonstrate that DNA methylation is a rapid process that is secondary to gene silencing. Moreover, we demonstrate that reexpression of MLL2 is sufficient to reactivate the methylated *MagohB* promoter.

MATERIALS AND METHODS

Cell lines and cell culture. Wild-type mouse ES cells (129P2 background; here termed E14) and *Mll2*⁻/⁻, *Mll2*^F/F, and *Mll2*^F/+ ES cells (5, 15, 16)

FIG 1 KMT2B is required for *MagohB* expression and maintenance of an open chromatin structure on the *MagohB* promoter. (A) Schematic depiction of the *Mll2* alleles in wild-type (WT *Mll2*) and *Mll2*$^{-/-}$ cells. The *Mll2*$^-$ allele contains a STOP cassette composed of a splice acceptor (SA), an internal ribosome entry sequence (IRES), the β-galactosidase gene (*lacZ*), a neomycin resistance gene (*neo*), two polyadenylation signals (pA), and a transcriptional terminator sequence (not shown). Black boxes, *Mll2* exons; E14, wild-type (WT) ES cell line; FRT, FLP recombination target. (B) *MagohB* mRNA expression in wild-type and knockout cells. *MagohB* expression is normalized against *Gapdh* mRNA expression. Bars represent the means plus SDs of at least 3 measurements. (C) Schematic of the structure of the *MagohB* locus. CS1, CS2, and CS3, conserved intronic regions. Arrows indicate the positions of the two DNase I-hypersensitive sites detected within an extended genomic region. (D) Southern blot visualizing the DHSs located within the BamHI fragment using the probe abutting the downstream BamHI site, as indicated in panel C. Arrows, the two DNase I-hypersensitive sites detected. The last two lanes serve as a DNase I-nondigested control (BamHI) and as size markers (BamHI plus EcoRI/BglII [BamHI + EcoRI]).

were provided by A. F. Stewart and were grown in high-glucose Dulbecco modified Eagle medium supplemented with 15% serum (PAA Gold fetal bovine serum), 1,000 U/ml leukemia inhibitory factor (ESGRO; Millipore), 25 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 1× nonessential amino acids (Sigma), and 0.15 mM monothioglycerol at 37°C in 5% CO_2 on tissue culture-grade plastics at a density of 10^4 cells/cm^2. Cells were split every 2 to 3 days as necessary by brief trypsinization in an appropriate volume of 1× trypsin-EDTA at room temperature.

Genotyping. The *Mll2*$^{F/F}$ and *Mll2*$^{E/+}$ ES cells were tested for recombination of the *Mll2* alleles twice by Southern blotting and after that by PCR and agarose gel electrophoresis every time that they were induced with 4-hydroxytamoxifen (OHT). OHT was added to the culture medium at a final concentration of 10^{-7} M. The genotyping PCR was performed using primers 145se (CGGAGGAAGAGAGCAGTGACG) and 147as (GGACAGGAGTCACATCTGCTAGG). The 145se/147as primer pair detects all *Mll2* alleles.

Disruption of RNA polymerase II by α-amanitin and DRB. Cells were grown as described above. 5,6-Dichlorobenzimidazole-1-β-D-ribofuranoside (DRB; Sigma) or α-amanitin (Sigma) was added to the culture

medium to give a final concentration of 100 μM or 5 μg/ml, respectively. The cells were cultured for up to 24 h in DRB and up to 48 h in α-amanitin and then harvested using a method suited for the downstream analyses.

Transfections. pCAGGS-FlpO-IRES-puro transfections were performed in 6-well plates using Lipofectamine LTX with Plus reagent (Invitrogen) according to the manufacturer's instructions. The transfected cells were grown in puromycin-containing medium for 24 h, harvested as a bulk population, and expanded for the time periods indicated in the relevant figures. Cells were cotransfected with 100-fold less of a green fluorescent protein (GFP)-expressing plasmid. Fluorescence-activated cell sorter analysis revealed that at least 95% of cells expressed GFP.

DNase I-hypersensitive site (DHS) mapping. The method employed for DNase I treatment is an adaptation of the method described by Pfeifer and Riggs (17). Southern blot transfer and hybridization were performed as described by Cockerill (18).

***In vivo* footprinting.** Footprinting experiments were performed as described by Tagoh et al. (19), using Phusion polymerase (New England Biolabs) and the GC-specific buffer instead of the suggested *Pfu* polymerase. Micrococcal nuclease (MNase) digestions were performed using the

FIG 2 Cre-mediated deletion of *Mll2* results in *MagohB* silencing 4 days after OHT treatment. (A) Cre-mediated deletion of *Mll2* exon 2 results in a frameshift and generation of a STOP codon in exon 3. *F*, conditional allele; *FC*, null allele. (B) (Top) *Mll2* Southern blot distinguishing the different *Mll2* alleles before and after OHT treatment. The image shown is a representative of 2 experiments. WT, wild-type allele; d, days. (Bottom) Quantitation of the Southern blot. The intensity quantification was performed using the Quantity One software suite (Bio-Rad). (C) *MagohB* mRNA expression after *Mll2* deletion. *MagohB* expression is normalized against *Gapdh* mRNA expression. Bars represent the means plus SDs of 4 measurements.

same method used for DNase I. Primer sequences used in footprinting assays are available upon request.

Measurement of DNA methylation. (i) Pyrosequencing. Genomic DNA was treated with sodium bisulfite using an EZ-DNA methylation kit from Zymo Research according to the manufacturer's instructions. Bisulfite-converted DNA was used as a PCR template to amplify the *MagohB* promoter using biotinylated primers specific for the converted DNA sequence (forward sequence, AGTAGAGAAGGTAGAAATTATTATTTATAG; reverse sequence, [biotin]-CTCTTAAAAATCTCTTACTTCCTCTTC). PCR products were purified using streptavidin-coated magnetic beads and prepared for sequencing using a third sequencing primer (SEQ [GGTAGAAATTATTATTTATAGATAT]).

(ii) HpaII digestion. Five hundred micrograms of genomic DNA was digested to completion with HpaII. The digests were used as the template for quantitative PCRs (QPCRs) with primers flanking a single HpaII site on the *MagohB* promoter (*MagohB* HpaII forward primer, TTCTCTTGGGGGTCTCTTGCTTCC; *MagohB* HpaII reverse primer, CGCGTCACCAAGGGCGCGTT). Data were subsequently normalized against a PCR amplicon on the *Oct4* promoter that does not contain an HpaII site.

(iii) Methylated DNA immunoprecipitation (MeDIP) and hydroxymethylated DNA immunoprecipitation (HmeDIP). Five micrograms per immunoprecipitation (IP) of anti-methylated C (ab10805; Abcam) and anti-hydroxymethylated C (ab106918; Abcam) antibody each was incubated with 10 μl protein G Dynabeads (10004D; Life Technologies) for 2 h at 4°C with rotation. One hundred microliters purified genomic DNA (2 μg/IP) was added to the bead-antibody complexes, and the mixture was incubated overnight at 4°C with rotation. The beads were separated using a magnetic separator and washed once with each of the following: wash buffer 1 (20 mM Tris, pH 8.0, 2 mM EDTA, 1% Triton X-100, 0.1% SDS, 150 mM NaCl), wash buffer 2 (20 mM Tris, pH 8.0, 2 mM EDTA, 1% Triton X-100, 0.1% SDS, 500 mM NaCl), and TE-NaCl buffer (10 mM Tris, pH 8.0, 1 mM EDTA, 50 mM NaCl). Finally, the immunoprecipitated DNA was eluted in 0.1 M NaHCO₃, 1% SDS, 200 mM NaCl containing 200 μg/ml proteinase K by a 4-h incubation at 65°C. The eluted DNA was purified using an Agencourt Ampure XP PCR cleanup kit and used as the template for a QPCR with primers specific for the *MagohB* promoter (forward primer, TACTCCGGTAGGAACGAAA; reverse primer, CTCCAATGCGAACCTTCAGT).

RNA and protein purification. Total RNA and protein were purified using an RNeasy kit (Qiagen) according to the manufacturer's instructions.

cDNA synthesis and QPCR. Moloney murine leukemia virus reverse transcriptase (Invitrogen) was used to reverse transcribe 1 μg total RNA according to the manufacturer's instructions. QPCR was performed on an ABI 7900HT or ABI 7500 real-time PCR instrument using ABI SYBR green master mix. Initial data analysis (threshold/baseline) was performed by ABI SDS software, and further analyses were performed in the Microsoft Excel program. Standard curve quantitation was performed for all QPCR experiments. The primer sequences used in mRNA expression measurements were as follows: for *Gapdh* (glyceraldehyde-3-phosphate dehydrogenase gene), forward primer ACCTGCCAAGTATGATGACATCA and reverse primer GGTCCTCAGTGTAGCCCAAGAT; for *Oct4*, forward primer AGGTGGAACCAACTCCCGAG and reverse primer GCTTCAGCAGCTTGGCAAC; and for *MagohB*, forward primer CGGGCATAAGGGCAAGTTT, primary RNA forward primer TGGGACTATGAAATTGTCTTTACC, and reverse primer AATTACTGTTGTTGGCATATGTAAGCTT.

ChIP. Chromatin immunoprecipitation (ChIP) assays were performed as described previously (20) with modifications. ES cells were fixed *in situ* by addition of formaldehyde (final concentration, 1%) in the culture medium and incubation for 12 min. Nuclei were prepared from the fixed cells, and the contained chromatin was sheared by sonication in a Diagenode Bioruptor (high setting, 8 cycles of 30 min of pulse and 30 min of pause at 4°C). Immunoprecipitation was performed using antibodies against the RNA Pol II carboxy-terminal domain (CTD) (ab5408; Abcam), H3K4me₃ (07-473; Millipore), and acetylated H3K9 (H3K9ac; ab4441; Abcam). The immunoprecipitated DNA was amplified by QPCR as described above. Primer sequences used in ChIP-QPCR were as follows: for the *MagohB* promoter, forward primer TACTCCGGTAGGAACGAAA and reverse primer CTCCAATGCGAACCTTCAGT; for the *Oct4* promoter, forward primer TGGGCTGAAATACTGGGTTC and reverse primer TTGAATGTTCGTGTGCCAAT.

SDS-PAGE and Western blotting. Whole-cell extracts from equal amounts of cells were separated on a Bio-Rad 4 to 20% gradient mini-Protean TGX precast gel. Proteins were transferred onto a nitrocellulose membrane by wet transfer. Membranes were blocked with 5% (wt/vol)

FIG 3 KMT2B is required to maintain activating histone marks and a stable RNA polymerase II complex on the *MagohB* promoter. (A) DNase I *in vivo* footprinting of the *MagohB* promoter in OHT-treated *Mll2^F/F* and *Mll2^F/+* cells. White bar, region protected from DNase I; black bars, hypersensitive regions; G, naked genomic DNA subjected to a Maxam-Gilbert G reaction prior to ligation-mediated PCR; ctrl, *in vitro* DNase I-digested DNA; arrow, TSS. Time after OHT treatment is indicated above the relevant lanes. *Mll2^−/−* ES cells were included to demonstrate the DNase I digestion pattern in the inactive state. Annotation on the left (in base pairs) is relative to the TSS. Primers on the *Oct4* promoter were used to verify equal DNase I digestion of all samples. The image shows a representative of 2 experiments. (B to D) ChIP-QPCR assays using antibodies against H3K4me$_3$ (B), H3K9ac (C), and the RNA polymerase II CTD (D). Data for histone modifications were corrected for nucleosome density, as determined by a histone H3 ChIP assay. Data for RNA polymerase II are corrected for the signal obtained with input material. Data shown are internally normalized against the signal obtained with primers for the *Oct4* promoter and presented in relation to the occupancy measured in E14 wild-type ES cells. Bars represent the means plus SDs of at least 4 measurements.

bovine serum albumin in Tris-buffered saline–Tween. West-pico chemiluminescence (Thermo Fisher) was used to visualize the results according to the manufacturer's instructions. The primary antibodies used were ab5408 (Pol II CTD), ab5095 (serine-2-phosphorylated [phospho-S2] elongating form of Pol II), and ab86601 (Nup188) and are available from Abcam. The appropriate horseradish peroxidase-conjugated secondary antibodies were sourced from Jackson ImmunoResearch.

RESULTS

***MagohB* expression requires KMT2B.** *Mll2^−/−* ES cells were employed to investigate the mechanism of *MagohB* transcriptional regulation. These cells harbor a gene-trapping cassette in intron 1 of both alleles of *Mll2* (Fig. 1A). The nascent *Mll2* transcript is spliced to the cassette, thus preventing expression of wild-type *Mll2.* We measured *MagohB* steady-state mRNA levels by reverse transcription-QPCR in the wild-type ES cell line E14 and *Mll2^−/−* ES cells. As reported previously (15), *MagohB* expression was abolished in *Mll2^−/−* ES cells (Fig. 1B), suggesting that KMT2B is absolutely required for *MagohB* expression.

In order to dissect the molecular mechanism by which KMT2B activates or maintains transcription from the *MagohB* promoter, we first had to identify potential *cis* regulatory elements on the *Magoh2B* locus. Three conserved intronic regions which could be regulating *MagohB* expression were identified (through the UCSC genome browser's mammalian conservation plots) and were termed conserved sequence 1 (CS1), CS2, and CS3 (Fig. 1C). We then employed DNase I-hypersensitive site (DHS) mapping to examine the entire *MagohB* gene and the immediate 5′ flanking region. Hybridization with probes on either side of the restriction fragment revealed the presence of two DHSs, termed HSp and HS1 (Fig. 1D; results from hybridization with only one probe are shown). HSp forms over the *MagohB* CpG island promoter and is present only in E14 wild-type cells. Loss of HSp in the *Mll2^−/−* cells suggests that KMT2B is involved in maintenance of the open chromatin conformation of the *MagohB* promoter. HS1 forms over a simple repeat element (Fig. 1D and data not shown), possibly because the DNA sequence of the repeat element is unfavorable for nucleosome assembly. In summary, from our data, it is highly likely that the main element driving expression of *MagohB* is its CpG island promoter.

***MagohB* is transcriptionally silenced 4 days after *de novo Mll2* deletion.** To establish the order of events that lead to *MagohB* silencing after KMT2B depletion, we employed ligand-dependent conditional mutagenesis (21). The *Mll2^F/+* and *Mll2^F/F* ES cells ubiquitously express Cre-ERT2 from the *Rosa26* locus and have one or two conditional *Mll2* alleles, respectively (described in more detail in references 5 and 15). Cre-ERT2 activation by 4-hy-

FIG 4 Nucleosome remodelling over the *MagohB* promoter 2 days after *Mll2* deletion. (A) MNase *in vivo* footprinting visualizing the vicinity of the *MagohB* transcription start site in OHT-treated *Mll2*[F/F] cells. Gray bar covering the TSS, moderately increased MNase sensitivity; white bars, protected regions when comparing digestion patterns observed at the 8-day time point to those at the 0-h time point; G, G reaction; arrow, TSS. The time after OHT induction is indicated at the top of each lane. Annotation on the left (in base pairs) is relative to the TSS. Primers on the *Oct4* promoter were used to verify equal MNase digestion of all samples. The image shows a representative of 2 experiments. (B and C) Nucleosome density over the *MagohB* promoter 0, 2, and 4 days after OHT treatment of *Mll2*[F/+] (B) and *Mll2*[F/F] (C) cells. Nucleosome density was measured by histone H3 ChIP followed by QPCR with primers centered on the positions indicated on the *x* axis. chr2, chromosome 2, which represents a transcriptionally inactive control region. Bars represent the means plus SDs of at least 4 measurements.

droxytamoxifen (OHT) results in deletion of *Mll2* exon 2, causing a frameshift and introducing a stop codon within exon 3 (Fig. 2A). We measured the efficiency and kinetics of Cre-mediated recombination by Southern blotting (Fig. 2B) and found that recombination was complete 24 h after OHT induction. These results confirm previous studies using the same ES cell system (15), showing similar recombination kinetics. The study described above had also demonstrated an approximately 50% reduction of KMT2B protein 12 h after Cre activation. Importantly, no outgrowth of nonrecombined cells was observed at up to 8 days postinduction, as detected by the absence of the *Mll2*[F] allele in either cell line.

We measured *MagohB* steady-state mRNA levels over a 4-day period after OHT induction (Fig. 2C). Although *Mll2* deletion was complete within 1 day after addition of OHT, the first transcriptional effects on *MagohB* were observed at 2 days postinduction. This discrepancy can be attributed to both the stability of the *MagohB* mRNA and the half-life of KMT2B. Subsequently, a nearly complete depletion of *MagohB* mRNA was observed 4 days after OHT induction. No significant downregulation of *MagohB* was observed in *Mll2*[F/+] cells, indicating that one allele of *Mll2* is sufficient to maintain *MagohB* expression.

Chromatin structure of the *MagohB* promoter is perturbed after KMT2B depletion. To gain insight into the mechanistic details of the different steps of *MagohB* silencing, we performed DNase I footprinting experiments over a time course of 8 days (Fig. 3A). We observed a characteristic protection from DNase I digestion around the transcription start site (TSS) flanked by hypersensitive regions, suggesting the presence of a protein assem-

bly, most likely the RNA polymerase II preinitiation complex. This pattern was maintained in the *Mll2*[F/+] cells throughout this time course, consistent with the aforementioned maintenance of *MagohB* mRNA levels in those cells. In contrast, the DNase I digestion pattern observed in *Mll2*[F/F] cells over the *MagohB* TSS was altered 4 days after OHT induction, coinciding with the observed *MagohB* mRNA depletion. The digestion pattern observed 8 days after OHT induction very closely resembles the pattern observed in *Mll2*[−/−] cells. This experiment demonstrates that the maintenance of DNase I-hypersensitive chromatin over the TSS requires the presence of KMT2B.

To correlate the reduction in nuclease accessibility with changes in histone modification patterns, we employed ChIP-QPCR studies. These assays revealed that loss of KMT2B and downregulation of gene expression are associated with loss of the active H3K4me$_3$ and H3K9ac marks (Fig. 3B and C), which was first observed 2 days after OHT induction in *Mll2*[F/F] cells. The levels of both histone marks decreased to near background levels at 4 days postinduction, concomitantly with *MagohB* mRNA depletion. RNA polymerase II levels closely correlated with the levels of these two histone marks (Fig. 3D). Loss of only one *Mll2* allele (*Mll2*[F/+] cells) had no effect on the chromatin environment of the *MagohB* promoter. These results support the view that KMT2B and/or the H3K4me$_3$ mark is required for RNA polymerase II association with the *MagohB* promoter.

Chromatin architecture at *MagohB* promoter. DHSs and active promoters have previously been reported to be devoid of nucleosomes (22–26). MNase preferentially cuts in nucleosomal

FIG 5 Rapid DNA methylation of the *MagohB* CpG island after KMT2B depletion. Cytosine modification levels on a part of the *MagohB* CpG island promoter in *Mll2*$^{F/+}$ (A) and *Mll2*$^{F/F}$ (B) cells were measured by bisulfite conversion and subsequent pyrosequencing. The cells were induced with OHT at 0 days and harvested at the time points indicated on the *z* axis. DNA methylation levels measured in *Mll2*$^{-/-}$ cells are inserted as a separate point on the *z* axis for comparison. Each point on the *x* axis represents an individual CpG dinucleotide. (C) Data presented in panels A and B summarized in a box plot format. Analysis was performed using SPSS. Hatched line, median DNA methylation level in *Mll2*$^{-/-}$ cells; black bars, median CpG methylation over the region examined (bp −48 to +69); boxes, 95% confidence interval; whiskers, 99% confidence interval; open circle, outlier. (D) MeDIP-QPCR with primers specific for the *MagohB* promoter in *Mll2*$^{F/+}$ and *Mll2*$^{F/F}$ ES cells 0, 4, and 8 days after OHT treatment. 5′-meC, 5′ methylated C. Bars represent the means plus SDs of 3 experiments. (E) HmeDIP-QPCR with primers specific for the *MagohB* promoter in *Mll2*$^{F/+}$ and *Mll2*$^{F/F}$ ES cells 0, 4, and 8 days after OHT treatment. 5′-hmeC, 5′ hydroxy-methylated C. Bars represent means + SDs of 3 experiments.

linker regions in chromatin (27, 28), which can be visualized as strong double-strand cuts in high-resolution mapping assays (19). In addition, large nonhistone DNA-protein complexes can also be indicated by flanking MNase cuts (29). We therefore employed MNase footprinting to examine the chromatin architecture of the *MagohB* promoter after deletion of *Mll2*. Identical MNase digestion patterns were observed in untreated *Mll2*$^{F/F}$ and *Mll2*$^{F/+}$ cells with strong MNase cuts flanking the TSS and the active RNA polymerase II complex. This digestion pattern, especially the strong flanking sites, remained unchanged in *Mll2*$^{F/+}$ cells up to 8 days after OHT induction. In *Mll2*$^{F/F}$ cells, however, it was altered 2 days after OHT induction (Fig. 4A). Changes in MNase accessibility were also observed further downstream (data not shown). These findings confirmed the DNase I data demonstrating that upon loss of KMT2B, nuclease accessibility on the *MagohB* promoter and surrounding region was altered. To clarify whether these changes were due to nucleosome repositioning or eviction of the basal transcription machinery and/or other protein factors, we

performed ChIP experiments using an antibody raised against histone H3 (Fig. 4B and C). These experiments demonstrated that nucleosomes on the *MagohB* CpG island promoter were only loosely positioned, if at all, consistent with previously reported findings with CpG island promoters (30). Most importantly, we did not detect major alterations in the nucleosome occupancy pattern at the *MagohB* promoter up to 8 days after OHT treatment in *Mll2*$^{F/+}$ (Fig. 4B) or *Mll2*$^{F/F}$ (Fig. 4C) ES cells.

DNA methylation occurs soon after transcriptional silencing. To directly investigate whether DNA methylation is a silencing initiating or maintaining event, we measured DNA methylation levels on the *MagohB* CpG island promoter region by bisulfite conversion and pyrosequencing over an 8-day time course. A total of 19 CpG sites distributed between bp −48 and +69 from the transcription start site were examined in this assay. The results showed no significant difference in DNA methylation in *Mll2*$^{F/+}$ cells over the duration of this time course (Fig. 5A). In contrast, increased DNA methylation at the *MagohB* promoter

FIG 6 The H3K4me$_3$ mark and protection from DNA methylation persist on the *MagohB* promoter, despite a block in transcription and a decrease in RNA polymerase II association. (A) Western blot analysis of DRB- and α-amanitin-treated *Mll2^{F/F}* cells, using whole-cell protein extracts. Arrow, band for phospho-serine 2 RNA polymerase II; asterisk, a nonspecific band. Dimethyl sulfoxide (DMSO)-treated samples were used as a control to exclude drug carrier effects. An antibody against nucleoporin Nup188 was used to verify equal sample loading. The image shown is a representative of 2 individual experiments. (B) Reverse transcription-QPCR detecting primary *MagohB* RNA in DRB- and α-amanitin-treated cells. Data presented here are normalized to the level of 18S rRNA, which is transcribed by RNA polymerase I. Bars represent the means plus SDs of 4 measurements. (C) ChIP with antibodies against H3K4me$_3$ and RNA polymerase II CTD. Data for histone modifications are corrected for nucleosome density, as determined by a histone H3 IP assay. Data for RNA polymerase II are corrected for input. The data presented are plotted as the fold change over the results for dimethyl sulfoxide-treated cells. Bars represent the means plus SDs of 4 measurements. (D) DNA methylation levels were measured by QPCR with primers spanning a single HpaII site after HpaII digestion. Methylation levels of the same CpG dinucleotide 8 days after OHT treatment of *Mll2^{F/F}* cells (*FC/FC*) are shown for comparison. Data presented here were normalized over an amplicon on the *Oct4* promoter that does not contain an HpaII site. N/A, not assayed. Dimethyl sulfoxide-treated cells were used to exclude any drug carrier effects. Bars represent the means plus SDs of 4 measurements.

was evident in *Mll2^{F/F}* cells 4 days after OHT induction (Fig. 5B). At this time point, the H3K4me$_3$ and H3K9ac histone marks along with RNA polymerase II had already been removed and transcription had ceased. We therefore conclude that DNA methylation cannot be responsible for initiating *MagohB* silencing in those cells. As no clear bias toward methylation (or protection from methylation) of specific CpG dinucleotides was observed, the three-dimensional graphs presented in Fig. 4A and B were summarized in a simpler box plot format (Fig. 5C). This representation revealed a significant (at 95% confidence) overall increase in CpG methylation on the *MagohB* promoter in *Mll2^{F/F}* cells 4 days after OHT treatment. At the 8-day time point, CpG methylation on the *MagohB* promoter in *Mll2^{F/F}* cells equalled the levels measured in *Mll2^{−/−}* cells. As this method cannot distinguish between cytosine methylation and hydroxymethylation, we performed MeDIP and HmeDIP assays coupled with QPCR. We measured an increase in methylcytosine levels on the *MagohB* promoter exclusively in *Mll2^{F/F}* cells at 4 and 8 days after OHT treatment (Fig. 5D), but hydroxymethylcytosine levels in both *Mll2^{F/+}* and *Mll2^{F/F}* ES cells were low (Fig. 5E). Importantly, the levels of this modification did not change after KMT2B depletion, verifying that what we detected by bisulfite conversion and pyrosequencing is indeed DNA methylation.

Transcription and RNA polymerase II are dispensable for the maintenance of the H3K4me$_3$ mark and for protection from DNA methylation. A recent study reports that the *Drosophila* homologue of KMT2B—Trx—is found to rapidly reassociate with

nascent DNA after the passage of the replication fork, while H3K4-methylated histones are detected only much later (31). Additionally, a previous report has shown that KMT2A remains bound on highly condensed mitotic chromosomes and marks genes that will be rapidly and highly induced upon entry of the cell into G$_1$ phase (32). During cell division, transcription ceases and RNA polymerase II is evicted from DNA. KTM2 proteins in higher eukaryotes therefore appear to be able to bind independently of RNA polymerase II association. To gain insight into the role of KMT2B in the absence of transcription and/or RNA polymerase II, *Mll2^{F/F}* cells were treated with DRB or α-amanitin. DRB blocks transcriptional elongation by inhibiting p-TEFb enzymatic activity (33, 34). α-Amanitin binds the active site of RNA polymerase II, and this complex is subsequently targeted for degradation (35). Western blotting using whole-cell extracts demonstrated that the serine-2-phosphorylated elongating form of RNA polymerase II was depleted after 16 h of DRB treatment, while a 24- or 48-h α-amanitin treatment greatly reduced total RNA polymerase II levels (Fig. 6A). As expected, *MagohB* primary transcripts (Fig. 6B) and steady-state mRNA (data not shown) were barely detectable following treatment with either of the two drugs. *Gapdh* expression levels were found to be just above detection limits (data not shown), demonstrating that this effect was not confined to *MagohB*. Importantly, 18S rRNA could be readily detected, as RNA polymerase I is reported to be unaffected by either of these drugs (data not shown).

We next examined the chromatin state at the *MagohB* pro-

FIG 7 Reactivation of the endogenous *Mll2* alleles in *Mll2*$^{-/-}$ ES cells is sufficient to reactivate *MagohB*. (A) The stop cassette was excised by FlpO-mediated recombination, allowing transcription of full-length *Mll2*. Black boxes, *Mll2* exons. (B) *MagohB* and *Mll2* expression relative to expression levels in E14 wild-type ES cells. pCAGGS-FlpO-puro-transfected *Mll2*$^{-/-}$ cells were harvested at 14 days posttransfection. Mock, pMAX-GFP-transfected *Mll2*$^{-/-}$ ES cells. Bars represent the means plus SDs of at least 4 measurements. (C) H3K4me$_3$ ChIP followed by QPCR with primers specific for the loci indicated on the *x* axis. FlpO-transfected cells were cultured for 14 days posttransfection. Bars represent the means plus SDs of at least 4 measurements. (D) MeDIP-QPCR with primers specific for the *MagohB* promoter in *Mll2*$^{F/F}$ and mock- and FlpO-transfected *Mll2*$^{-/-}$ ES cells, as indicated. Data are presented in relation to the enrichment measured in mock-transfected *Mll2*$^{-/-}$ cells. FlpO-transfected cells were harvested at the time points indicated on the *x* axis. Bars represent the means plus SDs of 3 experiments. (E) HmeDIP-QPCR with primers specific for the *MagohB* promoter in *Mll2*$^{F/F}$ and mock- and FlpO-transfected *Mll2*$^{-/-}$ ES cells, as indicated. Data are presented in relation to the enrichment measured in mock-transfected *Mll2*$^{-/-}$ cells. FlpO-transfected cells were harvested at the time points indicated on the *x* axis. Bars represent the means plus SDs of 3 experiments.

moter by ChIP-QPCR. We did not observe any difference in RNA polymerase II occupancy or H3K4me$_3$ levels in DRB-treated cells (Fig. 6C). We measured an approximately 50% reduction in RNA polymerase II occupancy over the *MagohB* promoter in cells treated with α-amanitin, accompanied by an approximately 2-fold increase in H3K4me$_3$ levels. The increase in H3K4me$_3$ could be explained by the loss of H3K4-specific demethylases as a result of RNA polymerase II inhibition. These findings support the notion that H3K4me$_3$ deposition and maintenance on the *MagohB* promoter do not require RNA polymerase II recruitment and transcription.

To test whether the reduction in elongation or RNA polymerase II occupancy increased DNA methylation at the *MagohB* CpG island promoter, we examined DNA methylation levels after DRB or α-amanitin treatment by HpaII digestion and QPCR. We did not observe any increase in methylation of this particular CpG dinucleotide following either treatment. This result suggests that in the presence of KMT2B, protection from DNA methylation does not depend on productive transcriptional elongation and is not affected by a severe depletion of RNA polymerase II binding. The presence of KMT2B and/or the H3K4me$_3$ mark is sufficient to protect the *MagohB* promoter from the action of DNA methyltransferases.

Reactivation of endogenous *Mll2* alleles is sufficient to revert *MagohB* to the active state. In order to examine whether DNA

methylation permanently locks the *MagohB* promoter in the inactive state, we reactivated the endogenous *Mll2* alleles in *Mll2*$^{-/-}$ cells by transient expression of the FlpO recombinase. Expression of FlpO results in removal of the stop cassette and expression of wild-type KMT2B from the endogenous locus (Fig. 7A). *Mll2*$^{-/-}$ cells were transfected with a pCAGGS-FlpO-puro plasmid and enriched by culturing in 1 μg/ml puromycin-containing medium for 24 h. Successful deletion of the stop cassette and reactivation of *Mll2* were verified by genotyping PCR (data not shown) and *Mll2* steady-state mRNA expression measurement (Fig. 7B). Upon reintroduction of KMT2B (14 days posttransfection), *MagohB* mRNA could be readily detected (Fig. 7B), suggesting that KMT2B action can overcome the repressive barrier posed by DNA methylation. *MagohB* reactivation was accompanied by the reestablishment of the H3K4me$_3$ mark on the *MagohB* promoter (Fig. 7C), as shown by ChIP-QPCR assays performed at the same time point. Both cytosine methylation (Fig. 7D) and 5′ hydroxymethylation (Fig. 7E) were detected and progressively decreased on the *MagohB* promoter. Our results suggest that reactivation of the endogenous *Mll2* alleles and physiological levels of KMT2B expression are sufficient to reestablish the normal H3K4me$_3$ pattern and to induce DNA demethylation, most likely via a 5′ hydroxymethylcytosine intermediate.

FIG 8 Model for *MagohB* silencing following KMT2B depletion. KMT2B is normally recruited to the *MagohB* promoter by transcription factors, by interaction of the PHD fingers with H3K4me₃, or through CXXC domain binding to nonmethylated CpG dinucleotides. After *Mll2* deletion, H3K4me₃ and H3K9ac are gradually depleted from the *MagohB* promoter and RNA polymerase II is lost, leading to transcriptional silencing. This is finally followed by DNA methylation and loss of the DNase I-hypersensitive site.

DISCUSSION

KMT2B is required to establish and maintain an active chromatin environment and recruit RNA polymerase II to the *MagohB* promoter. The inducible *Mll2*-knockout system allowed us to dissect the order of events leading to *MagohB* silencing and demonstrate that it occurs in a sequential fashion. After KMT2B depletion, the levels of the H3K4me₃ mark decrease (herein and reference 15) with a concomitant decrease in both H3K9 acetylation and RNA polymerase II association with the *MagohB* promoter, resulting in transcriptional silencing. Additionally, the *MagohB* promoter lacks DNase I hypersensitivity in the absence of KMT2B, as shown by our DHS mapping experiments in *Mll2*⁻/⁻ cells.

In summary, from our data it is likely that KMT2B forms a platform that coordinates the assembly of the basal transcription machinery via multiple interactions. The transactivation domain of KMT2A has been shown to interact directly with CBP/p300-containing histone acetyltransferase (HAT) complexes (36). HAT complexes are known to act as large multiprotein scaffolds that can mediate interactions between transcription factors and the basal transcription machinery (37). KMT2B may be involved in stabilizing the recruitment of CBP/p300-containing complexes, which can in turn recruit the transcriptional apparatus. The pre-initiation complex may be further stabilized by TF_IID binding to

H3K4-trimethylated nucleosomes (38, 39) flanking the *MagohB* promoter. This model predicts that loss of KMT2B would result in loss of histone acetylation and RNA polymerase II, which is precisely what we observed.

KMT2B action is not dependent on transcription or the presence of RNA polymerase II. Our experiments using DRB and α-amanitin demonstrate that in the presence of KMT2B, RNA polymerase II recruitment and transcriptional elongation are largely dispensable for the maintenance of H3K4 trimethylation. This result is consistent with the hypothesis that MLL proteins (KMT2A to KMT2D) operate differently from yeast Set1 and have a causal role in transcriptional activation. Previous studies have hinted to such a mechanism, as depletion of KMT2A resulted in changes in RNA polymerase II distribution on KMT2A target genes (12, 13). Moreover, it has been demonstrated that CpG islands recruit H3K4 methyltransferases regardless of their transcriptional activity (40). Our experiments provide direct evidence that neither active transcription nor the presence of the RNA polymerase II preinitiation complex is required to maintain the H3K4me₃ mark over a CpG island promoter, further suggesting that MLL (KMT2A to KMT2D) proteins act upstream of RNA polymerase II recruitment.

KMT2B confers protection from DNA methylation. How CpG islands are protected from DNA methylation has been a long-standing subject of research. Our data clearly demonstrate that loss of the H3K4me₃ mark results in the rapid onset of DNA methylation at multiple CpG dinucleotides over the *MagohB* CpG island promoter. Moreover, transcriptional elongation and RNA polymerase II did not appear to play a role in *MagohB* methylation protection, as illustrated by our experiments using DRB and α-amanitin. In turn, we show that reexpression of KMT2B is sufficient to induce demethylation of the methylated *MagohB* promoter, the reestablishment of its normal H3K4me₃ pattern, and the activation of transcription (Fig. 7D and E). This indicates that once all activators are present, the RNA polymerase II complex efficiently reassociates and overrides the silent state. It has previously been demonstrated that H3K4me₃ may confer protection from DNA methylation (41), as the DNA methyltransferase common subunit—DNMT3L—can interact only with unmethylated H3K4. As such, KMT2 catalytic activity would preclude DNA methyltransferase recruitment, thus conferring protection from DNA methylation to KMT2 target promoters. In addition, physically retaining KMT2B on chromatin during replication may further protect from DNA methyltransferase action. The detailed dissection of these processes is a current subject of further experimentation outside the scope of this study.

KMT2B in CpG island promoter regulation. Based on our results, we propose a model for the role of KMT2B in *MagohB* transcriptional regulation (Fig. 8). After KMT2B depletion, the H3K4me₃ mark is either actively removed or diluted over consecutive cell divisions, resulting in loss of the H3K9ac mark. RNA polymerase II can no longer associate with the *MagohB* promoter, as its recruitment may be facilitated or stabilized by direct interactions of TF_IID with the H3K4me₃ mark (38, 39) and interactions with CBP/p300-containing HAT complexes (36, 37). As the preinitiation complex is removed, transcription ceases. After the H3K4me₃ mark and/or KMT2B has been removed from the *MagohB* promoter, DNA methyltransferases are able to target and *de novo* methylate the MagohB CpG island. We believe that such a scenario is avoided at most genes by the high level of redundancy

within the KMT2 family of histone methyltransferases. However, the specific developmental defects of individual KMT2 family member knockouts indicate that windows in development exist where the dynamic activation of genes becomes dependent on a specific family member. Currently, the transcription factors recruiting KMT2A/B-containing complexes are not known. The *MagohB* promoter binds Sp1 and Sp3 *in vitro*, but no binding could be detected in ChIP experiments, and deletion of either factor individually did not influence *MagohB* mRNA levels (data not shown). Whatever recruits KMT2A/B complexes, our model helps to explain why once a transcriptional network has been destabilized in the context of tumorigenesis, CpG island promoters become vulnerable to gene silencing.

ACKNOWLEDGMENTS

REFERENCES

1. **Bannister AJ, Kouzarides T.** 2011. Regulation of chromatin by histone modifications. Cell Res. **21:**381–395.
2. **Ruthenburg AJ, Allis CD, Wysocka J.** 2007. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol. Cell **25:**15–30.
3. **Ernst P, Mabon M, Davidson AJ, Zon LI, Korsmeyer SJ.** 2004. An Mll-dependent Hox program drives hematopoietic progenitor expansion. Curr. Biol. **14:**2063–2069.
4. **Yagi H, Deguchi K, Aono A, Tani Y, Kishimoto T, Komori T.** 1998. Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood **92:**108–117.
5. **Glaser S, Schaft J, Lubitz S, Vintersten K, van der Hoeven F, Tufteland KR, Aasland R, Anastassiadis K, Ang SL, Stewart AF.** 2006. Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development **133:**1423–1432.
6. **Collins EC, Rabbitts TH.** 2002. The promiscuous MLL gene links chromosomal translocations to cellular differentiation and tumour tropism. Trends Mol. Med. **8:**436–442.
7. **Daser A, Rabbitts TH.** 2005. The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin. Cancer Biol. **15:**175–188.
8. **Slany RK.** 2005. When epigenetics kills: MLL fusion proteins in leukemia. Hematol. Oncol. **23:**1–9.
9. **Slany RK.** 2009. The molecular biology of mixed lineage leukemia. Haematologica **94:**984–993.
10. **Smith E, Lin C, Shilatifard A.** 2011. The super elongation complex (SEC) and MLL in development and disease. Genes Dev. **25:**661–672.
11. **Ng HH, Robert F, Young RA, Struhl K.** 2003. Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity. Mol. Cell **11:**709–719.
12. **Milne TA, Dou Y, Martin ME, Brock HW, Roeder RG, Hess JL.** 2005. MLL associates specifically with a subset of transcriptionally active target genes. Proc. Natl. Acad. Sci. U. S. A. **102:**14765–14770.
13. **Wang P, Lin C, Smith ER, Guo H, Sanderson BW, Wu M, Gogol M, Alexander T, Seidel C, Wiedemann LM, Ge K, Krumlauf R, Shilatifard A.** 2009. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol. Cell. Biol. **29:**6074–6085.
14. **Terranova R, Agherbi H, Boned A, Meresse S, Djabali M.** 2006. Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc. Natl. Acad. Sci. U. S. A. **103:**6629–6634.
15. **Glaser S, Lubitz S, Loveland KL, Ohbo K, Robb L, Schwenk F, Seibler**

16. **J, Roellig D, Kranz A, Anastassiadis K, Stewart AF.** 2009. The histone 3 lysine 4 methyltransferase, Mll2, is only required briefly in development and spermatogenesis. Epigenetics Chromatin **2:**5. doi:10.1186/1756-8935 -2-5.
16. **Lubitz S, Glaser S, Schaft J, Stewart AF, Anastassiadis K.** 2007. Increased apoptosis and skewed differentiation in mouse embryonic stem cells lacking the histone methyltransferase Mll2. Mol. Biol. Cell **18:**2356–2366.
17. **Pfeifer GP, Riggs AD.** 1991. Chromatin differences between active and inactive X chromosomes revealed by genomic footprinting of permeabilized cells using DNase I and ligation-mediated PCR. Genes Dev. **5:**1102–1113.
18. **Cockerill PN.** 2000. Identification of DNaseI hypersensitive sites within nuclei. Methods Mol. Biol. **130:**29–46.
19. **Tagoh H, Cockerill PN, Bonifer C.** 2006. In vivo genomic footprinting using LM-PCR methods. Methods Mol. Biol. **325:**285–314.
20. **Forsberg EC, Downs KM, Christensen HM, Im H, Nuzzi PA, Bresnick EH.** 2000. Developmentally dynamic histone acetylation pattern of a tissue-specific chromatin domain. Proc. Natl. Acad. Sci. U. S. A. **97:**14494–14499.
21. **Logie C, Stewart AF.** 1995. Ligand-regulated site-specific recombination. Proc. Natl. Acad. Sci. U. S. A. **92:**5940–5944.
22. **Workman JL, Roeder RG.** 1987. Binding of transcription factor TFIID to the major late promoter during in vitro nucleosome assembly potentiates subsequent initiation by RNA polymerase II. Cell **51:**613–622.
23. **Almer A, Rudolph H, Hinnen A, Horz W.** 1986. Removal of positioned nucleosomes from the yeast PHO5 promoter upon PHO5 induction releases additional upstream activating DNA elements. EMBO J. **5:**2689–2696.
24. **Fletcher TM, Xiao N, Mautino G, Baumann CT, Wolford R, Warren BS, Hager GL.** 2002. ATP-dependent mobilization of the glucocorticoid receptor during chromatin remodeling. Mol. Cell. Biol. **22:**3255–3263.
25. **Reik A, Schutz G, Stewart AF.** 1991. Glucocorticoids are required for establishment and maintenance of an alteration in chromatin structure: induction leads to a reversible disruption of nucleosomes over an enhancer. EMBO J. **10:**2569–2576.
26. **Richard-Foy H, Hager GL.** 1987. Sequence-specific positioning of nucleosomes over the steroid-inducible MMTV promoter. EMBO J. **6:**2321–2328.
27. **Axel R.** 1975. Cleavage of DNA in nuclei and chromatin with staphylococcal nuclease. Biochemistry **14:**2921–2925.
28. **Clark RJ, Felsenfeld G.** 1971. Structure of chromatin. Nat. New Biol. **229:**101–106.
29. **Lefevre P, Witham J, Lacroix CE, Cockerill PN, Bonifer C.** 2008. The LPS-induced transcriptional upregulation of the chicken lysozyme locus involves CTCF eviction and noncoding RNA transcription. Mol. Cell **32:**129–139.
30. **Fenouil R, Cauchy P, Koch F, Descostes N, Cabeza JZ, Innocenti C, Ferrier P, Spicuglia S, Gut M, Gut I, Andrau JC.** 2012. CpG islands and GC content dictate nucleosome depletion in a transcription-independent manner at mammalian promoters. Genome Res. **22:**2399–2408.
31. **Petruk S, Sedkov Y, Johnston DM, Hodgson JW, Black KL, Kovermann SK, Beck S, Canaani E, Brock HW, Mazo A.** 2012. TrxG and PcG proteins but not methylated histones remain associated with DNA through replication. Cell **150:**922–933.
32. **Blobel GA, Kadauke S, Wang E, Lau AW, Zuber J, Chou MM, Vakoc CR.** 2009. A reconfigured pattern of MLL occupancy within mitotic chromatin promotes rapid transcriptional reactivation following mitotic exit. Mol. Cell **36:**970–983.
33. **Fraser NW, Sehgal PB, Darnell JE.** 1978. DRB-induced premature termination of late adenovirus transcription. Nature **272:**590–593.
34. **Marshall NF, Peng J, Xie Z, Price DH.** 1996. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J. Biol. Chem. **271:**27176–27183.
35. **Nguyen VT, Giannoni F, Dubois MF, Seo SJ, Vigneron M, Kedinger C, Bensaude O.** 1996. In vivo degradation of RNA polymerase II largest subunit triggered by alpha-amanitin. Nucleic Acids Res. **24:**2924–2929.
36. **Cosgrove MS, Patel A.** 2010. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J. **277:**1832–1842.
37. **Chan HM, La Thangue NB.** 2001. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. **114:**2363–2373.
38. **van Ingen H, van Schaik FM, Wienk H, Ballering J, Rehmann H, Dechesne AC, Kruijzer JA, Liskamp RM, Timmers HT, Boelens R.** 2008.

Structural insight into the recognition of the H3K4me3 mark by the TFIID subunit TAF3. Structure **16**:1245–1256.

39. **Vermeulen M, Mulder KW, Denissov S, Pijnappel WW, van Schaik FM, Varier RA, Baltissen MP, Stunnenberg HG, Mann M, Timmers HT.** 2007. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell **131**:58–69.

40. **Thomson JP, Skene PJ, Selfridge J, Clouaire T, Guy J, Webb S, Kerr AR, Deaton A, Andrews R, James KD, Turner DJ, Illingworth R, Bird A.** 2010. CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature **464**:1082–1086.

41. **Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument-Bromage H, Tempst P, Lin SP, Allis CD, Cheng X, Bestor TH.** 2007. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature **448**:714–717.